Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

Voices of biotech.

Amit I, Baker D, Barker R, Berger B, Bertozzi C, Bhatia S, Biffi A, Demichelis F, Doudna J, Dowdy SF, Endy D, Helmstaedter M, Junca H, June C, Kamb S, Khvorova A, Kim DH, Kim JS, Krishnan Y, Lakadamyali M, Lappalainen T, Lewin S, Liao J, Loman N, Lundberg E, Lynd L, Martin C, Mellman I, Miyawaki A, Mummery C, Nelson K, Paz J, Peralta-Yahya P, Picotti P, Polyak K, Prather K, Qin J, Quake S, Regev A, Rogers JA, Shetty R, Sommer M, Stevens M, Stolovitzky G, Takahashi M, Tang F, Teichmann S, Torres-Padilla ME, Tripathi L, Vemula P, Verdine G, Vollmer F, Wang J, Ying JY, Zhang F, Zhang T.

Nat Biotechnol. 2016 Mar;34(3):270-5. doi: 10.1038/nbt.3502. No abstract available.

PMID:
26963549
2.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F.

Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8.

PMID:
26855148
3.

Role of non-coding sequence variants in cancer.

Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Gerstein M.

Nat Rev Genet. 2016 Feb;17(2):93-108. doi: 10.1038/nrg.2015.17. Epub 2016 Jan 19. Review.

PMID:
26781813
4.

Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.

Rubin MA, Girelli G, Demichelis F.

Eur Urol. 2016 Apr;69(4):557-60. doi: 10.1016/j.eururo.2015.10.040. Epub 2015 Nov 10.

5.

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, Carreira S, Goodall J, Wingate A, Ferraldeschi R, Tunariu N, Flohr P, De Giorgi U, de Bono JS, Demichelis F, Attard G.

Sci Transl Med. 2015 Nov 4;7(312):312re10. doi: 10.1126/scitranslmed.aac9511.

PMID:
26537258
6.

Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model.

Lecca P, Casiraghi N, Demichelis F.

Front Genet. 2015 Oct 13;6:309. doi: 10.3389/fgene.2015.00309. eCollection 2015.

7.

SPOP mutation leads to genomic instability in prostate cancer.

Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, Sboner A, de Bono JS, Demichelis F, Houvras Y, Rubin MA.

Elife. 2015 Sep 16;4. pii: e09207. doi: 10.7554/eLife.09207.

8.

Prostate cancer: Intrapatient heterogeneity in prostate cancer.

Beltran H, Demichelis F.

Nat Rev Urol. 2015 Aug;12(8):430-1. doi: 10.1038/nrurol.2015.182. Epub 2015 Jul 28. No abstract available.

PMID:
26215693
9.

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J, Greco N, McNary TJ, Herrscher E, Wilkes D, MacDonald TY, Xue H, Vacic V, Emde AK, Oschwald D, Tan AY, Chen Z, Collins C, Gleave ME, Wang Y, Chakravarty D, Schiffman M, Kim R, Campagne F, Robinson BD, Nanus DM, Tagawa ST, Xiang JZ, Smogorzewska A, Demichelis F, Rickman DS, Sboner A, Elemento O, Rubin MA.

JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313.

10.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-28. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

11.

ASEQ: fast allele-specific studies from next-generation sequencing data.

Romanel A, Lago S, Prandi D, Sboner A, Demichelis F.

BMC Med Genomics. 2015 Mar 1;8:9. doi: 10.1186/s12920-015-0084-2.

12.

In-silico identification and functional validation of allele-dependent AR enhancers.

Garritano S, Romanel A, Ciribilli Y, Bisio A, Gavoci A, Inga A, Demichelis F.

Oncotarget. 2015 Mar 10;6(7):4816-28.

13.

Tumor clone dynamics in lethal prostate cancer.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G.

Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448.

14.

Unraveling the clonal hierarchy of somatic genomic aberrations.

Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F.

Genome Biol. 2014 Aug 26;15(8):439. doi: 10.1186/s13059-014-0439-6.

15.

Genetic predisposition to prostate cancer: Update and future perspectives.

Demichelis F, Stanford JL.

Urol Oncol. 2015 Feb;33(2):75-84. doi: 10.1016/j.urolonc.2014.04.021. Epub 2014 Jul 2. Review.

PMID:
24996773
16.

Second generation imaging of nuclear/cytoplasmic HIV-1 complexes.

Francis AC, Di Primio C, Quercioli V, Valentini P, Boll A, Girelli G, Demichelis F, Arosio D, Cereseto A.

AIDS Res Hum Retroviruses. 2014 Jul;30(7):717-26. doi: 10.1089/AID.2013.0277. Epub 2014 Jun 6.

17.

SPOP mutations in prostate cancer across demographically diverse patient cohorts.

Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA.

Neoplasia. 2014 Jan;16(1):14-20.

18.

A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.

Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R, Sollie T, Helenius G, Andersson SO, Demichelis F, Andrén O, Rubin MA.

Appl Immunohistochem Mol Morphol. 2014;22(2):136-41. doi: 10.1097/PDM.0b013e31829e0484.

PMID:
24517914
19.

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. doi: 10.1158/1055-9965.EPI-13-1180. Epub 2014 Feb 10.

20.

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.

Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.

Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk